Functional Systems Scores and Expanded Disability Status Scale Score Evaluations in the ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis
Started October 26, 2022
154
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Started August 25, 2022
242
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis: Pooled Post Hoc Analyses of the ULTIMATE I and II Studies
Started June 27, 2022
185
Ublituximab Efficacy Outcomes in Relapsing Multiple Sclerosis Patient Subgroups in the ULTIMATE I and II Studies
Started June 27, 2022
166
Improved Quality of Life With Ublituximab in the ULTIMATE I and II Studies in Relapsing Multiple Sclerosis
Started June 27, 2022
241
Infusion-Related Reactions With Ublituximab in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis
Started June 2, 2022
162
Improved Cognitive Processing Speed With Ublituximab in Patients With Highly Active Relapsing Multiple Sclerosis
Started June 2, 2022
186
Reduced Disease Progression With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis
Started June 2, 2022
196
Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS)
Started April 5, 2022
261
Infusion-Related Reactions (IRRs) with Ublituximab in Patients with Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses from the Phase 3 ULTIMATE I and II Studies
Started April 3, 2022
258
Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Started April 3, 2022
285
Disability Improvements with Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations from the Phase 3 ULTIMATE I and II Studies
Started April 3, 2022
212